Parliamentary QA
Govt's Position on the Use of Traditional Chinese Medicine (TCM) Lianhua Qingwen Jiao Nang capsules
9 May 2022
This article has been migrated from an earlier version of the site and may display formatting inconsistencies.
NOTICE PAPER NO. 1130
NOTICE OF QUESTION FOR ORAL ANSWER
FOR THE SITTING OF PARLIAMENT ON 9 MAY 2022
Mr Chua Kheng Wee Louis
MP for Sengkang GRC
Question No. 2878
To ask the Minister for Health what is the Government’s position on the use of the traditional Chinese medicine (TCM) Lianhua Qingwen Jiao Nang capsules in Singapore.
Answer
Lianhua Qingwen Jiaonang (LHQW) 莲花清瘟胶囊 capsules are classified as Chinese Proprietary Medicines (CPMs) in Singapore, approved for the relief of cold and flu symptoms. CPMs are not intended for the prevention, treatment or cure of specific diseases.
We are aware of claims circulating on social media platforms that LHQW can be used to prevent or treat COVID-19. To date, there is no conclusive evidence from controlled clinical studies to substantiate those claims. Locally, there is an ongoing local study to investigate the effectiveness of LHQW in reducing COVID-19 symptoms.